A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - ...

The Ibero-American Consortium gathers over 3000 DNA samples to drive precision strategies for rheumatoid arthritis and ...

Shares of Tempus AI ( TEM 14.71%) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the ...

In a report recently published in the American Journal of Health-System Pharmacy, the Ochsner Health system investigates the ...

Panelists discuss how the future of polycythemia vera (PV) management will be shaped by advancements in targeted therapies, ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...

Radiopharmaceuticals are transforming modern medicine, while simultaneously intensifying the pressures on pharmaceutical ...

EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS | Embrace the transformative power of multimodal AI-driven analytics to accelerate innovation and realize the full potential of ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence for healthcare, has announced the launch of Fuses, a groundbreaking initiative set to transform precision medicine.